John Tilton - 06 Jan 2022 Form 4 Insider Report for Biohaven Pharmaceutical Holding Co Ltd.

Role
Chief Commercial Officer
Signature
/s/ George Clark, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
06 Jan 2022
Net transactions value
-$112,320
Form type
4
Filing time
07 Jan 2022, 20:18:48 UTC
Previous filing
26 Nov 2021
Next filing
03 Oct 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BHVN Common Shares Options Exercise $0 +1,250 +34% $0.000000 4,955 06 Jan 2022 Direct F1
transaction BHVN Common Shares Tax liability $68,247 -551 -11% $123.86* 4,404 06 Jan 2022 Direct F2
transaction BHVN Common Shares Options Exercise $0 +875 +20% $0.000000 5,279 07 Jan 2022 Direct
transaction BHVN Common Shares Tax liability $44,074 -342 -6.5% $128.87* 4,937 07 Jan 2022 Direct F2
holding BHVN Common Shares 1,614 06 Jan 2022 By JET Ventures LLC

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BHVN Restricted Share Unit Award Options Exercise $0 -1,250 -33% $0.000000 2,500 06 Jan 2022 Common Shares 1,250 Direct F3, F4, F5
transaction BHVN Employee Stock Option (right to buy) Award $0 +7,000 $0.000000 7,000 07 Jan 2022 Common Shares 7,000 $128.87 Direct F6
transaction BHVN Restricted Share Unit Award Award $0 +3,500 $0.000000 3,500 07 Jan 2022 Common Shares 3,500 Direct F3, F5, F7
transaction BHVN Restricted Share Unit Award Options Exercise $0 -875 -25% $0.000000 2,625 07 Jan 2022 Common Shares 875 Direct F3, F5, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This balance includes 271 shares that were acquired through the Biohaven Employee Share Purchase Plan on May 31, 2021, and 17 shares that were acquired through the Biohaven Employee Share Purchase Plan on November 30, 2021.
F2 No shares were sold - these shares were withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted share units.
F3 Each restricted share unit represents the contingent right to receive one common share of the Issuer.
F4 The reporting person was granted 5,000 restricted share units on January 6, 2021, vesting in four equal installments on January 6, 2021, 2022, 2023 and 2024, subject to the reporting person's continued service with the Issuer at each vesting date.
F5 Not applicable.
F6 The shares underlying this option vest in four equal installments on January 7, 2022, 2023, 2024 and 2025, subject to the reporting person's continuous service with the Issuer at each vesting date.
F7 The reporting person was granted 3,500 restricted share units on January 7, 2022, vesting in four equal installments on January 7, 2022, 2023, 2024 and 2025, subject to the reporting person's continued service with the Issuer at each vesting date.

Remarks:

Exhibit List: Exhibit 24: Power of attorney